Bristol Myers Squibb

News

BMS' deucravacitinib psoriasis pill could launch next year a...

Bristol-Myers Squibb has phase 3 data from its deucravacitinib psoriasis pill, showing it outperformed Amgen’s rival Otezla in patients with moderate to severe disease.

News

FDA approves BMS' multiple myeloma CAR-T Abecma

The FDA has approved Bristol-Myers Squibb’s Abecma (idecabtagene vicleucel) for multiple myeloma, the first cell therapy to treat the disease.

News

Merck gets a leg-up for Keytruda in first-line kidney cancer

New phase 3 data have shored up the position of Merck & Co’s cancer immunotherapy Keytruda in the increasingly competitive first-line kidney cancer market.

News

Heat Bio’s shares ignite on Opdivo combination data in NSCLC

The pairing of Heat Biologics’ lead drug HS-110 with Bristol-Myers Squibb’s blockbuster checkpoint inhibitor Opdivo has boosted survival in patients with non-small cell lung cancer (NSCLC),

News

BMS finally gets FDA OK for liso-cel, sets $410k launch pric...

Bristol-Myers Squibb finally has FDA approval for its CAR-T therapy liso-cel, which has been cleared by the US regulator as Breyanzi for certain forms of large B-cell lymphoma.

News

BMS eyes May FDA verdict for MS drug Zeposia in ulcerative c...

Bristol-Myers Squibb’s commercial hopes for new multiple sclerosis drug Zeposia have yet to bear fruit thanks to the pandemic, but it’s already cued up a second indication for the would-be

BMS' deucravacitinib psoriasis pill could launch next year a...

FDA approves BMS' multiple myeloma CAR-T Abecma

Merck gets a leg-up for Keytruda in first-line kidney cancer

Heat Bio’s shares ignite on Opdivo combination data in NSCLC

BMS finally gets FDA OK for liso-cel, sets $410k launch pric...

BMS eyes May FDA verdict for MS drug Zeposia in ulcerative c...

CDC panel votes to scrap hepatitis B birth dose advice

How to meet your physicians where they are online

Bristol Myers Squibb

Editor's Picks